12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SMT 19969: Phase I started

Summit began a placebo-controlled Phase I trial to evaluate single and multiple ascending-doses of oral SMT 19969 in 56 healthy volunteers. Last month,...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >